Mode
Text Size
Log in / Sign up

Active tDCS shows large effect on life engagement in schizophrenia outpatients versus shamCan brain stimulation help people with schizophrenia feel more engaged with life?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret large tDCS effect on life engagement in schizophrenia as preliminary post-hoc evidence.

A randomized controlled trial investigated the effects of prefrontal transcranial direct current stimulation (tDCS) on life engagement in 50 outpatients living with schizophrenia. Participants received either active tDCS (15 weekday sessions at 2 mA, with anode over left DLPFC and cathode over right orbitofrontal cortex) or sham tDCS. The primary outcome was life engagement assessed using the PANSS-LE subscale.

Post-hoc analyses showed significantly greater reductions in PANSS-LE scores following active tDCS compared to sham stimulation, with a reported large effect size of 0.97. The study did not report absolute score changes, p-values, or confidence intervals for this outcome. Follow-up was conducted at 3.5 months.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuation rates, were not reported in the available evidence. The study's limitations were not specified, and funding or conflict of interest information was not reported.

The evidence is preliminary, derived from post-hoc analyses of a single RCT with a modest sample size. While the large effect size is notable, the lack of absolute numbers, confidence intervals, and comprehensive safety data limits clinical interpretation. These findings suggest tDCS may influence life engagement in schizophrenia but require confirmation in prospectively designed, adequately powered trials with pre-registered outcomes before clinical application can be considered.

For people living with schizophrenia, feeling disconnected from daily life—from work, hobbies, and relationships—can be one of the most difficult parts of the illness. A small study of 50 outpatients explored whether a non-invasive brain stimulation technique called tDCS could help. The researchers focused on stimulating specific prefrontal brain areas thought to be involved in motivation and engagement.

After 15 weekday sessions, the group receiving active stimulation showed significantly greater improvement in life engagement scores compared to the group receiving a sham (placebo) treatment. The researchers reported a 'large effect size,' which suggests the difference wasn't trivial, though they didn't provide the actual score changes or confidence intervals to show the range of possible effects.

It's important to understand what this study does and doesn't tell us. The analysis looking specifically at life engagement was done after the main trial ended—researchers went back to see if there was a signal. This makes the evidence preliminary. We don't know about side effects or how tolerable the treatment was, as that wasn't reported. The study was also quite small, so we can't generalize these findings to everyone with schizophrenia.

While the idea that a non-drug approach might help with life engagement is compelling, this is just an early signal. Much larger, carefully designed studies that measure life engagement as a primary goal from the start are needed to know if this approach truly makes a meaningful difference in people's lives.

What this means for you:
Early signal that brain stimulation might improve life engagement in schizophrenia, but evidence is very preliminary.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up3.5 mo
PublishedApr 2026
View Original Abstract ↓
INTRODUCTION: Life engagement (LE) is a patient-reported outcome measure (PROM), encompassing emotional, cognitive, social, and physical domains of functioning. While transcranial Direct Current Stimulation (tDCS) significantly improved cognitive and negative symptoms in schizophrenia, its effects on LE remain unexplored. We investigated whether prefrontal tDCS could improve LE in schizophrenia by conducting post-hoc analyses of a randomised, double-blind, sham-controlled trial. METHODS: Fifty outpatients living with schizophrenia were randomised to receive either active or sham tDCS (15 weekday sessions, 2 mA, anode: left DLPFC; cathode: right orbitofrontal cortex). LE was assessed using the PANSS-LE, a psychometrically validated subscale derived from the Positive and Negative Syndrome Scale (PANSS). Analyses examined within- and between-group changes, controlling for baseline symptom severity. RESULTS: Both active and sham-tDCS groups showed significant within-group improvements in LE. However, between-group analysis revealed significantly greater reductions in PANSS-LE scores following active-tDCS, with large effect size ( = 0.97). Moreover, LE improvements were not influenced by baseline levels of negative, cognitive, depressive symptoms, nor by illness severity, suggesting the specificity of LE as a treatment outcome. CONCLUSION: This study provides preliminary evidence that prefrontal tDCS may enhance LE in schizophrenia, independently of core symptom domains, supporting the integration of PROMs in neuromodulation research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.